Möchten Sie immer auf dem neuesten Stand bleiben?

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months  Data highlighted in oral presentation at AACR’s Clinical...

- Los análisis de la respuesta tumoral, los biomarcadores y los subgrupos del ensayo clínico VIRAGE de Fase 2b respaldan el mecanismo de acción inmunomediado de VCN-01 y demuestran una mejora en los...

SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies...

- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients...

Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

SAN DIEGO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a...

XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models  Consistent with Xilio’s clinically-validated masking technology,...

Westlake Village, CA, April 17, 2026 (GLOBE NEWSWIRE) -- JimStoppani.com, a digital fitness platform founded by exercise scientist Dr. Jim Stoppani, announced the launch of its Summer Shred...

Riverside, California, United States, April 17, 2026 (GLOBE NEWSWIRE) -- Opticore Eye Group, a leader in comprehensive eye care, is thrilled to announce the launch of its innovative Contact Lens...

Exton, PA, April 17, 2026 (GLOBE NEWSWIRE) -- New data from Spherix Global Insights’ Launch Dynamix™ service indicate that rebalancing agents are continuing to establish a foothold in hemophilia...